This roadmap provides clinicians with an overview of the management of individuals living with cardio-kidney-metabolic conditions and complications. To interact with the roadmap,
- type the eGFR number in the blue box at the top of the scale, or select the blue circle and slide it on the scale
- if albuminuria is present, click the box directly below the scale
- select from the bolded content in the box closest to the scale to see more details
Access the toolkits
The optimization of RAASi therapy and management of related complications was selected as the first implementation activity of the roadmap given the significant unmet need in this area, and the underutilization of RAASi therapy. The toolkit aims to provide focused, up-to-date, practical tools, and serve as a hands-on reference for nephrologists and cardiologists, as well as other healthcare professionals, involved in the multidisciplinary care of patients with cardio-renal complications.
Five educational and clinical tools were developed on the following topics: nuts-and-bolts of RAASi therapy; management of hyperkalemia; diet; managing acute declines in eGFR; and, patient knowledge.
Coming December 2024.
Coming in 2025.
The cardio-kidney-metabolic initiative is supported by unrestricted educational grants from AstraZeneca, CSL Vifor, Novo Nordisk, and Boehringer Ingelheim and its alliance partner, Lilly.